GlassScriptPhysician profile
Bryan L Gammon
NPI 1518134154
$40,130.96
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $12K · 2021: $248 · 2022: $94.96 · 2023: $460 · 2024: $60.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38,488.74 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $204.29 | 2019-2023 | Dupixent |
| Galderma Laboratories, L.P. | $179.31 | 2019-2021 | |
| Lilly USA, LLC | $174.95 | 2019-2023 | Taltz, Olumiant |
| Dermira, INC. | $130.19 | 2019 | |
| Abbvie INC. | $128.85 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $128.45 | 2019 | |
| Pfizer INC. | $91.05 | 2019-2023 | |
| Ucb, INC. | $88.70 | 2019-2021 | |
| Amgen INC. | $71.28 | 2022-2023 | Otezla |
| Janssen Biotech, INC. | $69.49 | 2020-2022 | |
| Leo Pharma INC. | $61.88 | 2023-2024 | Adbry |
| Merz North America, INC. | $55.81 | 2019 | |
| Henry Schein, INC. | $45.86 | 2021 | |
| Biofrontera INC. | $39.38 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.63 | 2021-2022 | |
| Alafair Biosciences, INC. | $36.89 | 2024 | Versawrap |
| E.R. Squibb & Sons, L.L.C. | $31.44 | 2023 | Sotyktu |
| Journey Medical Corporation | $26.78 | 2020-2022 | |
| Incyte Corporation | $22.19 | 2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $12.74 | 2023 | |
| Epi Health, LLC | $5.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Gammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.